（原标题：上海高端医疗器械集聚区启动；多家药企披露前三季度业绩预告） 这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！ 政策动向 上海：降低连续动态血糖监测等部分医疗服务价格 10月13日，上海市医疗保障局、上海市卫生健康委员会发布通知，根据国家医疗保障局《关于开展医疗 服务价格规范治理（第六批）的通知》（医保价采函〔2025〕138号）要求，按照医疗服务价格管理相 关规定，结合本市实际，现就本市降低部分医疗服务价格等事项通知如下：一、降低连续动态血糖监测 等部分医疗服务价格。附件所列医疗服务价格标准是本市公立医疗机构最高收费标准。鼓励医疗机构加 强管理、降低成本。二、各公立医疗机构应及时做好信息系统更新维护和价格公示等相关工作，按要求 将结算数据上传至国家医保信息平台，并接受医保、卫生健康等部门的监督，对违反本通知规定的，依 法严肃查处。三、医疗服务项目医保支付范围与标准，应当按照本市基本医疗保险有关规定执行。本通 知自2025年10月15日起执行，以前规定与本通知不符的，以本通知为准。 药械审批 人福医药：盐酸达泊西汀片获得药品注册证书 戴维医疗：全资子公司产品 ...

Macroeconomic Dynamics - Domestic gasoline and diesel prices will be reduced by 70 yuan and 75 yuan per ton respectively starting from October 13, 2023, due to the decline in international oil prices, resulting in a decrease of 0.06 yuan per liter for 92 and 95 gasoline and 0 diesel [2] - In the first three quarters, China's exports of high-tech products reached 3.75 trillion yuan, an increase of 11.9%, contributing over 30% to the overall export growth [5] International Relations - The Chinese Foreign Ministry criticized the U.S. for threatening to impose 100% tariffs on Chinese goods in retaliation for China's rare earth export controls, emphasizing that this approach is not the correct way to engage with China [3] - The Chinese Foreign Ministry clarified that recent export control measures on rare earths are unrelated to Pakistan's cooperation with the U.S. and are part of China's legal framework to enhance its export control system [4] Financial Institutions - UBS indicated that if the MSCI China Index drops to 74, it will find strong support, with investors likely to buy on dips, as the index has risen 36% since April [7] - New China Life Insurance expects a net profit increase of 45% to 65% year-on-year for the first three quarters of 2025, driven by reforms and improved asset allocation [9] - Everbright Bank plans to grant a comprehensive credit limit of 29 billion yuan to CITIC Financial Asset Management, constituting a related party transaction [10] - Bank of America raised its gold price forecast for next year to $5,000 per ounce [11] Market Data - The Shanghai Composite Index fell by 0.19%, with sectors like rare earth permanent magnets and gold showing strength, while over 3,600 stocks declined [12] - The financing balance in the two markets decreased by 34.95 billion yuan as of October 10, 2023 [13] - The Hong Kong Hang Seng Index dropped by 1.52%, with significant movements in the gold and semiconductor sectors [14] Company Dynamics - Microsoft will stop providing security updates and technical support for Windows 10 starting October 14, 2023, urging users to upgrade to Windows 11 [16] - Boehringer Ingelheim announced the launch of local production for its diabetes medication in China, enhancing supply stability in the market [17] - Meituan introduced a "full refund for side effects" feature for certain medications, allowing users to return products if they experience adverse effects within 21 days [18]

最新的本地化生产举措是公司深化在华战略布局的关键一步，标志着公司在中国市场实现了从商业运营向产业链纵深发展的跨越。 勃林格殷格翰是最早一批进入中国的跨国制药公司。该公司同样位于上海张江的中国生物制药基地也获得中国、美国、欧盟和日本在内的全球主要药品监管 机构的认证，成为国内少数拥有全球核心市场准入资质的"上海制造"生物制药合同生产企业。 近年来，伴随着中国生物医药行业的发展，以及患者对创新药需求的不断提升，跨国企业对中国生物医药领域启动了新一轮的投资，上海在全球生物医药领 域的地位和能级也持续上升。 就在10月12日，冯保和应邀出席第37届上海市市长国际企业家咨询会议（IBLAC）。他在会上指出："创新是上海战略的核心动力，而创新的发展离不开一 个鼓励创新、支持创新的市场环境。上海可通过机制创新，激发前沿成果，推动医疗健康产业高质量发展。" 诺华公司董事会主席乔恩礼（Giovanni Caforio）也在IBLAC上提出"上海全市血脂管理与心血管预防的数字化蓝图"，承诺积极参与我国公共卫生管理数字化 转型。该项目借鉴CARDIO4Cities项目，目标是助力上海打造数字公共卫生体系的全球标杆，达成《健康上海2 ...

10月13日，德国生物制药企业勃林格殷格翰宣布旗下重磅降糖药欧唐宁（利格列汀）在中国本地化生产 计划正式启动，这也是该公司首个在中国实现本地生产的人用药品。勃林格殷格翰表示，该计划将显著 提升欧唐宁在中国市场的供应稳定性。第一财经记者在现场采访注意到，勃林格殷格翰合作伙伴中国生 物制药公司CEO谢承润出席了启动仪式。（第一财经记者 钱童心） 勃林格殷格翰启动首个人用药中国本地化生产，中国生物制药CEO谢承润出席仪式 ...